Shattuck Labs, Inc.

NasdaqGS STTK

Shattuck Labs, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -62.56 M

Shattuck Labs, Inc. Operating Cash Flow is USD -62.56 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 26.95% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Shattuck Labs, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -85.65 M, a 4.17% change year over year.
Shattuck Labs, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -89.37 M, a -70.42% change year over year.
Shattuck Labs, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -52.44 M, a -92.54% change year over year.
Shattuck Labs, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -27.24 M.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqGS: STTK

Shattuck Labs, Inc.

CEO	Dr. Taylor H. Schreiber M.D., Ph.D.
IPO Date	Oct. 9, 2020
Location	United States
Headquarters	500 West 5th Street
Employees	75
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Key trends

Past 5 years